Glycogen metabolic dysfunction in T2DM with MASLD: linking α-hydroxybutyrate to GYS2 downregulation.

Zichen Zhang, Nuo Chen, Xiaojing Yuan, Jie Li, Wan Zhou

Abstract read

In one paragraph

Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zichen Zhang *Division of Life Sciences and Medicine, Department of Endocrinology and Metabolism, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.

Nuo Chen *Division of Life Sciences and Medicine, Department of Endocrinology and Metabolism, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.

Xiaojing YuanDivision of Life Sciences and Medicine, Department of Endocrinology and Metabolism, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.

Jie LiDepartment of Endocrinology, The People's Hospital of Tongcheng, Tongcheng, Anhui, China.

Wan ZhouDivision of Life Sciences and Medicine, Department of Endocrinology and Metabolism, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to investigate the molecular characteristics of T2DM with MASLD in a C57 mouse model, using multi-omics techniques to identify key nutritional metabolites that drive metabolic dysfunction. The goal was to reveal how metabolic disturbances are linked to transcriptional reprogramming, providing a new theoretical basis for nutritional biomarker discovery and targeted metabolic interventions. Methods: In this study, a mouse model of T2DM with MASLD was established using a high-fat diet (HFD) combined with intraperitoneal injection of low-dose streptozotocin (STZ). The mice were randomly allocated into three groups: a healthy control group, a MASLD-only group (HFD), and a T2DM with MASLD group (HFD + 40 mg/kg STZ, ip). Serum untargeted metabolomic analysis and hepatic transcriptomic sequencing were performed to identify significantly differential metabolites and transcripts between groups, specifically focusing on Results: Metabolomic and transcriptomic analyses revealed that Conclusion: This study reveals that

Indexed as

diabetes mellitusGYS2metabolic dysfunction-associated steatotic liver diseasemetabolomicsRNA-Seqα-hydroxybutyrate

Identifiers

PMID42440805

DOI10.3389/fnut.2026.1860017

PMCPMC13334271

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.